Clearmind Medicine (Clearmind Medicine) EBIT : $-4.52 Mil (TTM As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine EBIT?

Clearmind Medicine's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2024 was $-1.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2024 was $-4.52 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Clearmind Medicine's annualized ROC % for the quarter that ended in Jan. 2024 was -167.57%. Clearmind Medicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was -11,414.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Clearmind Medicine's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was 80.69%.

Clearmind Medicine EBIT Historical Data

The historical data trend for Clearmind Medicine's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine EBIT Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

EBIT

Get a 7-Day Free Trial

-0.08

-0.31

-2.17

-4.59

-4.56

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT	Get a 7-Day Free Trial															-1.83	-1.21	-0.83	-1.09	-1.38

Competitive Comparison of Clearmind Medicine's EBIT

For the Biotechnology subindustry, Clearmind Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's EV-to-EBIT falls into.

Clearmind Medicine EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.52 Mil.

Clearmind Medicine (NAS:CMND) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Clearmind Medicine's annualized ROC % for the quarter that ended in Jan. 2024 is calculated as:

	ROC % (Q: Jan. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2023 )	+	Invested Capital (Q: Jan. 2024 ))	/ count )
=	-5.536 * ( 1 - -17.32% )	/	( (3.232	+	4.52)	/ 2 )
=	-6.4948352	/	3.876
=	-167.57 %

where

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.305	-	0.477	-	( 3.987	-	max(0, 3.594	-	4.19	+	3.987	))
=	3.232

	Invested Capital		(Q: Jan. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.098	-	0.761	-	( 9.373	-	max(0, 5.026	-	9.843	+	9.373	))
=	4.52

Note: The Operating Income data used here is four times the quarterly (Jan. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Clearmind Medicine's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2023		Q: Jan. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.536	/	( ( (0.001 + max(-3.565, 0))	+	(0.096 + max(-4.646, 0)) )	/	2 )
=	-5.536	/	( ( 0.001	+	0.096 )	/	2 )
=	-5.536	/	0.0485
=	-11,414.43 %

where Working Capital is:

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.029)	-	(0.477	+	0	+	3.117)
=	-3.565

	Working Capital		(Q: Jan. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.316)	-	(0.761	+	0	+	4.201)
=	-4.646

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Clearmind Medicine's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jan. 2024 )
	=	-4.522	/	-5.604
	=	80.69 %

Clearmind Medicine EBIT Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.